Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Sabban, M. E.
Right arrow Articles by Bazarbachi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Sabban, M. E.
Right arrow Articles by Bazarbachi, A.
Related Collections
Right arrow Neoplasia
Right arrow Signal Transduction
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 October 2000, Vol. 96, No. 8, pp. 2849-2855

NEOPLASIA

Arsenic-interferon-alpha -triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kappa B activation

Marwan E. El-Sabban, Rihab Nasr, Ghassan Dbaibo, Olivier Hermine, Nour Abboushi, Frédérique Quignon, Jean Claude Ameisen, Françoise Bex, Hugues de Thé, and Ali Bazarbachi

From the Departments of Human Morphology, Internal Medicine, Biochemistry, and Pediatrics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; CNRS URA 1461 and Department of Hematology, Necker Hospital, Paris, France; UPR 9051 CNRS Laboratoire associé No. 11 du comité de Paris de la Ligue contre le Cancer, conventionné par l'Université Paris VII, Hôpital St Louis, Paris, France; INSERM CJF 9701, Hôpital Bichat, Paris, France; and Departement de Biologie Moléculaire, Université Libre de Bruxelles, Brussels, Belgium.

Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature activated T cells resistant to conventional chemotherapy. The viral transactivator protein Tax plays a critical role in HTLV-I-induced transformation and apoptosis resistance by inducing Ikappa B-alpha degradation, resulting in the activation of the NF-kappa Bpathway. In these HTLV-I-transformed cells, arsenic trioxide (As) and interferon (IFN)-alpha synergize to induce cell cycle arrest and apoptosis. We demonstrate that cell death induction is only partly dependent upon caspase activation and is not associated with modulation of bcl-2, bax, or p53 expression. However, combined As and IFN induce the degradation of Tax, associated with an up-regulation of Ikappa B-alpha resulting in a sharp decrease in RelA DNA binding nuclear factor (NF)-kappa B complexes because of the cytoplasmic retention of RelA. Taken the role of Tax in HTLV-I-induced transformation, its down-regulation probably accounts for cell death induction through inactivation of the NF-kappa B pathway. Such specific targeting of the viral oncoprotein by As-IFN treatment, reminiscent of As targeting of promyelocytic leukemia/retinoic acid receptor-alpha in acute promyelocytic leukemia, provides strong rational for combined As-IFN therapy in ATL patients.

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BMJ Case ReportsHome page
M.-O. Chandesris, D. Ghez, C. Besson, F. Suarez, R. Delarue, M.-T. Rubio, A. Bazarbachi, B. Varet, and O. Hermine
Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
BMJ Case Reports, August 10, 2009; 2009(aug10_1): bcr0120091449 - bcr0120091449.
[Abstract] [Full Text]


Home page
BloodHome page
G. Kchour, M. Tarhini, M.-M. Kooshyar, H. El Hajj, E. Wattel, M. Mahmoudi, H. Hatoum, H. Rahimi, M. Maleki, H. Rafatpanah, et al.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
Blood, June 25, 2009; 113(26): 6528 - 6532.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. C. Ramos, W. Harrington Jr, D. O'Mahony, J. E. Janik, A. L. Bittencourt, G. P. Taylor, et al.
Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting
J. Clin. Oncol., January 20, 2009; 27(3): 453 - 459.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
G P Taylor
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma
J. Clin. Pathol., December 1, 2007; 60(12): 1392 - 1396.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica, June 1, 2007; 92(6): 753 - 762.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Brown, M. Bellon, and C. Nicot
Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1
Blood, February 15, 2007; 109(4): 1653 - 1659.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Mahieux
HTLV-I and AZT: die another day
Blood, August 1, 2006; 108(3): 785 - 786.
[Full Text] [PDF]


Home page
BloodHome page
A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Blood, August 1, 2006; 108(3): 1021 - 1029.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X.-F. Che, C.-L. Zheng, S. Owatari, M. Mutoh, T. Gotanda, H.-C. Jeung, T. Furukawa, R. Ikeda, M. Yamamoto, M. Haraguchi, et al.
Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines
Blood, June 15, 2006; 107(12): 4880 - 4887.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Okudaira, M. Tomita, J.-N. Uchihara, T. Matsuda, C. Ishikawa, H. Kawakami, M. Masuda, Y. Tanaka, K. Ohshiro, N. Takasu, et al.
NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-{kappa}B signal pathway.
Mol. Cancer Ther., March 1, 2006; 5(3): 704 - 712.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood, February 15, 2006; 107(4): 1255 - 1264.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. M. B. Kerbauy, V. Lesnikov, N. Abbasi, S. Seal, B. Scott, and H. J. Deeg
NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
Blood, December 1, 2005; 106(12): 3917 - 3925.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Sinha-Datta, I. Horikawa, E. Michishita, A. Datta, J. C. Sigler-Nicot, M. Brown, M. Kazanji, J. C. Barrett, and C. Nicot
Transcriptional activation of hTERT through the NF-{kappa}B pathway in HTLV-I-transformed cells
Blood, October 15, 2004; 104(8): 2523 - 2531.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S.-J. Jeong, M. Radonovich, J. N. Brady, and C. A. Pise-Masison
HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity
Blood, September 1, 2004; 104(5): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Mohapatra, B. Chu, S. Wei, J. Djeu, P. K. Epling-Burnette, T. Loughran, R. Jove, and W. J. Pledger
Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2
Cancer Res., December 1, 2003; 63(23): 8523 - 8530.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Mathas, A. Lietz, M. Janz, M. Hinz, F. Jundt, C. Scheidereit, K. Bommert, and B. Dorken
Inhibition of NF-{kappa}B essentially contributes to arsenic-induced apoptosis
Blood, August 1, 2003; 102(3): 1028 - 1034.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Nasr, A. Rosenwald, M. E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de The, et al.
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells
Blood, June 1, 2003; 101(11): 4576 - 4582.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology, January 1, 2003; 2003(1): 1 - 13.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Hayashi, T. Hideshima, M. Akiyama, P. Richardson, R. L. Schlossman, D. Chauhan, N. C. Munshi, S. Waxman, and K. C. Anderson
Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment
Mol. Cancer Ther., August 1, 2002; 1(10): 851 - 860.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res., July 15, 2002; 62(14): 3893 - 3903.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood, May 1, 2002; 99(9): 3383 - 3389.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Mahieux, C. Pise-Masison, A. Gessain, John. N. Brady, R. Olivier, E. Perret, T. Misteli, and C. Nicot
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage
Blood, December 15, 2001; 98(13): 3762 - 3769.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. J. Murgo
Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
Oncologist, April 1, 2001; 6(90002): 22 - 28.
[Abstract] [Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020